Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, stock code: 600196.SH; 02196.HK) today announced an H share repurchase plan, under…
Browsing: BioTech
China Medical System Holdings Limited (CMS or the Group) is pleased to announce that its subsidiary, Dermavon Holdings Limited (Dermavon,…
CanSino Biologics Inc. (“CanSinoBIO,” 06185.HK/688185.SH) released its financial results for the first half of 2026. The Company reported revenue of…
– Sales of HuaTangNing reached 3.055 million packs in the first half of 2026, representing a 73% year-on-year increase; revenue…
Hengrui Pharma (“Hengrui” or “the Company”) today announced its financial results for the first half of 2026. During the reporting…
Everest Medicines (HKG: 01952) announced its interim results for the six months ended June 30, 2026. Everest delivered strong growth…
On August 16, 2026, CanSino Biologics Inc. (“CanSinoBIO”; HKEX: 06185/SHSE: 688185) announced that the New Drug Application (NDA) for its…
HONG KONG, August 7, 2026 – (ACN Newswire) – On August 3, 2026, Shaanxi Micot Pharmaceutical Technology Co., Ltd. (“Micot Pharma”;…
HONG KONG, July 24, 2026 – (JCN Newswire) – As Asia’s demographic structure evolves and health awareness continues to rise, the…
Everest Medicines (HKEX 1952.HK) announced the closing of its previously announced exclusive licensing and collaboration agreement with Travere Therapeutics, Inc.…
Avantor, a leading global provider of mission-critical products and services to the life sciences and advanced technology industries,announced today it…
June 26, 2026, Everest Medicines today announced that China’s National Medical Products Administration (NMPA) accepted the Biologics License Application (BLA)…
Everest Medicines (HKEX 1952.HK) announced that Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan…
China Medical System Holdings Limited (867.HK/8A8.SG) (CMS, or the Group) is pleased to announce that, the New Drug Application for…
Everest Medicines (HKEX 1952.HK)announced that it has entered into an exclusive licensing agreement with Australia Dimerix Limited (Dimerix), for the…
Everest Medicines today announced that it has entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co., Ltd. (“Vcare”),…
Hua Medicine (“the Company”, stock code: 2552.HK) presented a series of breakthrough research findings on dorzagliatin (Trade name: HuaTangNing, Trade name…
HighTide Therapeutics, Inc. (HKG: 2511), an innovative biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for cardiovascular–kidney–metabolic (CKM)…
Everest Medicines (HKEX 1952.HK) announced that it has entered into a commercialization license agreement with Beijing Mabworks Biotech Co., Ltd.…
Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc.…